Abacavir is a nucleoside reverse-transcriptase inhibitor that causes hypersensitivity reaction in 5 to 8% of HIV-infected users. Can a screening help limit or prevent the incidence of these reactions?

Abacavir, dolutegravir and lamivudine tablets for oral suspension, 60 mg/5 mg/30 mg, (Triumeq PD) had an estimated annual sale of USD 1.3 million in the US (IQVIA MAT September 2024). Lupin Limited is ...

At the time, people who took abacavir would sometimes develop rashes, fevers, or severe gastrointestinal symptoms, typically within days or weeks of starting the medication.

Abacavir Use Linked to Increased Incidence of MACE August 9, 2024 Former and current use of abacavir linked to higher incidence of MACE, but no association seen for other ART agents.

THURSDAY, Aug. 8, 2024 (HealthDay News) -- For patients with HIV in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial, use of abacavir was associated with an increased ...

Abacavir use showed similar trends for hard MACE events, defined as CV death, myocardial infarction, and stroke, but was not statistically significant, Fichtenbaum reported.

At study entry, 13% of participants were taking abacavir, 61% were taking tenofovir, 10% were taking zidovudine or stavudine, and 26% were taking PIs. In the investigators’ analyses, participants with ...

At study entry, 13% of participants were taking abacavir, 61% were taking tenofovir, 10% were taking zidovudine or stavudine, and 26% were taking PIs. Stroke Risk Calculator ...

Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, according to an exploratory ...

CJ Fichtenbaum et al. Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. International AIDS Conference. Friday, July 26, 2024 ...